Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$1.8M
Filings
99
Firms Hired
3
Active Period
2007–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to talks of future budget reconciliation package. Issues related to the reintroduction of the DIABETES Act (S.4037) in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade and the Sec. 232 Tariff investigation related to Medical Devices. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to National Coverage Determination revisions specifically in reference to durable infusion insulin pumps. Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act. Issues related to CMS finalized rule, DMEPOS Home Health Rule. Issues related to expansion of Competitive Bidding Program and implementation of CMS finalized rule relating to DMEPOS Home Health Rule. Issues related to combatting fraud, waste and abuse in the Medicare program - specifically related to the way continuous glucose monitors are billed in Medicare and potential solutions to vet durable medical equipment vendors at CMS. Issues related to wearable health care devices.
Client expense: $220,000 · Firm income: —
Matched citations: S.4037
Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to talks of future budget reconciliation package. Issues related to the reintroduction of the DIABETES Act (S.4037) in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade and the Sec. 232 Tariff investigation related to Medical Devices. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to National Coverage Determination revisions specifically in reference to durable infusion insulin pumps. Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act. Issues related to CMS finalized rule, DMEPOS Home Health Rule. Issues related to expansion of Competitive Bidding Program and implementation of CMS finalized rule relating to DMEPOS Home Health Rule. Issues related to wearable health care devices.
Client expense: $140,000 · Firm income: —
Matched citations: S.4037
Defund Extremism Working Group Act
2024 · fourth_quarter · Firm: INSULET CORPORATION
Issues related to the disease of diabetes, diabetes therapies and management of the disease of diabetes. Issues related to medical devices and medical device technology. Issues related to medical device sterilization methods. Issues related to Pharmacy Benefit Managers (PBMs) - no specific bills, but general discussions on impacts to medical devices in the pharmacy channel and impacts to patients. Issues in support of S.4532 H.R. 4532 - prior authorization reform. Issues related to real world evidence and real world data pertaining to medical devices and approval pathways. Issues related to artificial intelligence and predictive algorithms in medical device technology and innovations. Issues related to the filing of S. 5502 - DIABETES Act
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 4532
Improving Seniors’ Timely Access to Care Act of 2024
2024 · fourth_quarter · Firm: INSULET CORPORATION
Issues related to the disease of diabetes, diabetes therapies and management of the disease of diabetes. Issues related to medical devices and medical device technology. Issues related to medical device sterilization methods. Issues related to Pharmacy Benefit Managers (PBMs) - no specific bills, but general discussions on impacts to medical devices in the pharmacy channel and impacts to patients. Issues in support of S.4532 H.R. 4532 - prior authorization reform. Issues related to real world evidence and real world data pertaining to medical devices and approval pathways. Issues related to artificial intelligence and predictive algorithms in medical device technology and innovations. Issues related to the filing of S. 5502 - DIABETES Act
Client expense: $90,000 · Firm income: —
Matched citations: S.4532
Issues related to the disease of diabetes, diabetes therapies and management of the disease of diabetes. Issues related to medical devices and medical device technology. Issues related to medical device sterilization methods. Issues related to Pharmacy Benefit Managers (PBMs) - no specific bills, but general discussions on impacts to medical devices in the pharmacy channel and impacts to patients. Issues in support of S.4532 H.R. 4532 - prior authorization reform. Issues related to real world evidence and real world data pertaining to medical devices and approval pathways. Issues related to artificial intelligence and predictive algorithms in medical device technology and innovations. Issues related to the filing of S. 5502 - DIABETES Act
Client expense: $90,000 · Firm income: —
Matched citations: S. 5502
Defund Extremism Working Group Act
2024 · third_quarter · Firm: INSULET CORPORATION
Issues related to the disease of diabetes, diabetes therapies and management of the disease of diabetes. Issues related to medical devices and medical device technology. Issues related to medical device sterilization methods. Issues related to the Indian Health Service Issues related to Pharmacy Benefit Managers (PBMs) - no specific bills, but general discussions on impacts to medical devices in the pharmacy channel and impacts to patients. Issues in support of S.4532 H.R. 4532 - prior authorization reform. Issues related to real world evidence and real world data pertaining to medical devices and approval pathways. Issues related to artificial intelligence and predictive algorithms in medical device technology and innovations.
Client expense: $50,000 · Firm income: —
Matched citations: H.R. 4532
Improving Seniors’ Timely Access to Care Act of 2024
2024 · third_quarter · Firm: INSULET CORPORATION
Issues related to the disease of diabetes, diabetes therapies and management of the disease of diabetes. Issues related to medical devices and medical device technology. Issues related to medical device sterilization methods. Issues related to the Indian Health Service Issues related to Pharmacy Benefit Managers (PBMs) - no specific bills, but general discussions on impacts to medical devices in the pharmacy channel and impacts to patients. Issues in support of S.4532 H.R. 4532 - prior authorization reform. Issues related to real world evidence and real world data pertaining to medical devices and approval pathways. Issues related to artificial intelligence and predictive algorithms in medical device technology and innovations.
Client expense: $50,000 · Firm income: —
Matched citations: S.4532
Source: Senate LDA